

ArcherDX awards clinical research grants to medical investigators

Thirteen researchers will receive Archer NGS kits, on-site training and full access to Archer's bioinformatics platform to answer clinically relevant questions.

BOULDER, CO, USA, September 6, 2016 /EINPresswire.com/ -- ArcherDX, Inc., the leader in NGS-based gene fusion detection, recently awarded grants to thirteen physician-scientists under the Archer® Research Challenge Grants program.



Originally, five winners each were to

receive 24 Archer kits of the awardee's choosing (resulting in up to 192 reactions) as well as any on-site training and full access to the Archer Analysis bioinformatics platform. The program was extended to include a sixth full awardee and seven runner-up awards of six kits each due to the quality of program applications.

“

The goal of this program is to provide a means for physician-scientists to address clinically relevant and challenging questions in environments where funding for clinical research is limited.

Dr. Brian Kudlow, Vice President of R&D at ArcherDX

“The goal of this program is to provide a means for physician-scientists to address clinically relevant and challenging questions in environments where funding for clinical research is limited”, says Dr. Brian Kudlow, Vice President of R&D at ArcherDX.

Research projects were selected based on scientific and clinical relevance. The projects include novel fusion identification, cancer subtype characterization and the development of an RNA sequencing assay from liquid biopsy samples. Nearly half of the projects target sarcomas, and several others focus on hematological malignancies including AML, ALL and lymphoma. Lung, thyroid and gastric cancers

are also covered by some of the research projects.

[Learn about the Archer Research Challenge Grant winners and their projects.](#)

List of grant winners:

- Enrique de Alva, Virgen del Rocio University Hospital-Biomedical Institute of Seville
- Ryma Benayed, Memorial Sloan Kettering Cancer Center
- Florian Haller, University Hospital, Friedrich-Alexander University Erlangen-Nuremberg
- Hans Morreau, Leiden University Medical Center
- Russell (Rusty) Ryan, Massachusetts General Hospital

- Cecilia Yeung, Fred Hutchinson Cancer Research Center
- Anne McLeer, Grenoble Faculty of Medicine and University Hospital
- Alexander C. Mackinnon, Medical College of Wisconsin
- Stephanie Springborn, Medical College of Wisconsin
- Mary Chamberlin, Dartmouth Hitchcock Medical Center
- Merrida Childress, Vanderbilt University School of Medicine
- Leonardo Meza-Zepeda, Institute for Cancer Research, Oslo University Hospital

About ArcherDX

ArcherDX addresses the bottlenecks associated with using NGS in translational research by offering a robust platform for targeted sequencing applications.

By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry and easy-to-use, lyophilized reagents, Archer NGS assays generate highly enriched sequencing libraries to detect gene fusions, point mutations, CNVs and RNA abundance. Complemented by the Archer suite of bioinformatics software, ArcherDX technology dramatically enhances complex mutation identification and discovery.

ArcherDX is headquartered in Boulder, Colorado, USA.

<http://archerdx.com>

Jason Amsbaugh
ArcherDX
+1 303 357 9001
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.